Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sandeep Banga

Interventional Cardiology Carbondale, IL Medical Doctor

NPI 1003266149 CMS profile 2344422

409 W Oak St, Carbondale, IL 62901

Open in the dashboard

General payments

$37,199

457 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sandeep Banga of Carbondale, IL is reported in the CMS Open Payments database as having received $37,199 across 457 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,124 104
2024 General $11,949 115
2023 General $11,657 142
2022 General $2,663 60
2021 General $805 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sandeep Banga
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Sandeep Banga were reported at $10,124. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Sandeep Banga Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $805 $677 $233–$1,827 $132
2022 $2,663 $978 $333–$2,724 $149
2023 $11,657 $1,136 $382–$2,986 $160
2024 $11,949 $1,181 $395–$3,326 $164
2025 $10,124 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $11,537 38 payments
  2. Medtronic, Inc. $7,673 78 payments
  3. Boston Scientific Corporation $5,245 61 payments
  4. Bard Peripheral Vascular, Inc. $2,713 18 payments
  5. Edwards Lifesciences Corporation $1,968 20 payments
  6. Abiomed $1,056 15 payments
  7. E.R. Squibb & Sons, L.L.C. $840 29 payments
  8. AstraZeneca Pharmaceuticals LP $822 22 payments
  9. Shockwave Medical, Inc $787 8 payments
  10. Amgen Inc. $550 21 payments
  11. Other $4,008 147 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,325 369 payments
  2. Travel and Lodging $13,765 81 payments
  3. Grant $8,833 4 payments
  4. Education $276 3 payments
Products named General payments · program years 2021–2025
  1. PROSTAR $2,401 11 payments
  2. TurboHawk $1,919 14 payments
  3. JETSTREAM SC $1,590 6 payments
  4. Crosser iQ $1,473 13 payments
  5. RotarexS 6 F x 135 cm $1,129 4 payments
  6. ESPRIT $1,055 3 payments
  7. SAPIEN 3 Ultra RESILIA $946 16 payments
  8. AngioJet Ultra 5000A $916 2 payments
  9. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $866 1 payment
  10. COREVALVE EVOLUT R $835 14 payments
  11. Other $12,682 367 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

137

Median for Interventional Cardiology: 2,236

Drug cost

$8,829

Median for Interventional Cardiology: $380,412

Branded share of claims

8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 11 $7,494
Metoprolol Succinate Generic 41 $452
Carvedilol Generic 19 $227
Rosuvastatin Calcium Generic 12 $194
Nitroglycerin Generic 12 $146
Losartan Potassium Generic 14 $146
Atorvastatin Calcium Generic 12 $132
Amlodipine Besylate Generic 16 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $239
$239 — —
Repatha
  • Amgen Inc. $167
$167 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $139
$139 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $38
  • PFIZER INC. $36
$74 11 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

457 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record